Monday, July 9, 2012

Investors can Continue to Bring Claims Against KV Pharmaceutical

An interesting blog post entitled, Investors can Continue to Bring Claims Against KV Pharmaceutical, can be found here.  This blog discusses the United States Eighth Circuit Court of Appeals ruling that investors can continue to bring claims against KV Pharmaceutical Co. (KV) for making false or misleading statements to the U.S. Food and Drug Administration (FDA). The 8th Circuit issued its decision on  June 4, 2012.  The decision can be viewed here.  Investors claim they suffered $1.5 billion in losses because KV misled the FDA in its compliance reports, and subsequently shut down its manufacturing operations in 2009.

In March 2010, former KV subsidiary Ethex Corp pleaded guilty to two-felony counts of criminal fraud and agreed to pay $27.6 million in fines and restitution. In 2011,  KV's former chief executive, Marc Hermelin, pleaded guilty to misdemeanor violations of the Food, Drug and Cosmetic Act and was sentenced to 30 days in jail and ordered to pay $1.9 million in fines and forfeitures.

Sunday, July 8, 2012

Extra-label Drug Use in Veterinary Medicine


FDA Veterinarian Newsletter March/April 2003 Volume XVIII, No 2, by Gillian Comyn, D.V.M., M.P.H., D.A.C.V.P.M.

Introduction
Since 1994, when Congress passed the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA), veterinarians in the U.S. have enjoyed legitimate extra-label use (ELU) privileges. Veterinarians can safeguard ELU privileges by following AMDUCA, and by educating clients (particularly food animal producers) on AMDUCA and prudent drug use principles. This article outlines key points of AMDUCA in plain language.
Animal Medicinal Drug Use Clarification Act
Extra-label drug use (ELU) refers to the use of an approved drug in a manner that is not in accordance with the approved label directions. ELU of new animal drugs was considered illegal and permitted only as a matter of enforcement discretion until the passing of AMDUCA. AMDUCA amended the Federal Food, Drug, and Cosmetic Act (the Act), legalizing extra-label drug use by and under the order of a licensed veterinarian within the context of a valid veterinarian-client-patient relationship, and became effective in 1996 when implementing regulations (21 CFR Part 530) were published.
AMDUCA allows veterinarians to prescribe extra-label uses of certain approved animal drugs and approved human drugs for animals under specified conditions.
The key components and conditions of AMDUCA1 are as follows:
  • Veterinarian-Client-Patient Relationship (VCPR)
  • General Conditions for Extra-Label Use Under AMDUCA
  • Conditions for Extra-Label Use in Food Animals
  • Compounding Under AMDUCA
  • Prohibitions Under AMDUCA
Veterinarian-Client-Patient Relationship (VCPR)
The regulation defines a valid veterinarian-client-patient relationship as one in which:
  1. A veterinarian has assumed the responsibility for making medical judgments regarding the health of (an) animal(s) and the need for medical treatment, and the client (the owner of the animal or animals or other caretaker) has agreed to follow the instructions of the veterinarian;
  2. There is sufficient knowledge of the animal(s) by the veterinarian to initiate at least a general or preliminary diagnosis of the medical condition of the animal(s); and
  3. The practicing veterinarian is readily available for follow-up in case of adverse reactions or failure of the regimen of therapy. Such a relationship can exist only when the veterinarian has recently seen and is personally acquainted with the keeping and care of the animal(s) by virtue of examination of the animal(s), and/or by medically appropriate and timely visits to the premises where the animal(s) are kept.
General Conditions for Extra-Label Drug Use Under AMDUCA
  1. There is no animal drug approved for the intended use;
  2. Or, there is an animal drug approved for the intended use, but the approved drug is not in the required dosage form or concentration;
  3. Or, the approved drug has been found to be clinically ineffective when used as labeled;
  4. Or, if the intended use is in a non-food animal, an approved human drug can be used even if an approved animal drug is available.
  5. In food animals, use of approved human drugs is not permitted if (an) approved animal drug(s) can be used.
  6. RECORDKEEPING: The veterinarian must maintain records with animal identification (in food animal practices, on a group, herd, flock, or per-client basis). The records have to include: established name of the drug and its active ingredient, or if formulated from more than one ingredient, established name of each ingredient; condition treated; species of the treated animal(s); dosage administered; treatment duration; number of animals treated; and withdrawal, withholding, or discard time(s), for meat, milk, eggs, or any food from the animals treated. The veterinarian must keep these records for 2 years or as required by Federal or State law, whichever is greater. The records must be available at any reasonable times to FDA designated personnel, for copying and verifying.
  7. LABELING: The label on a drug dispensed for ELU, whether by a veterinarian or dispensed by a pharmacist on the order of a veterinarian, must have the following information: name and address of the prescribing veterinarian (and the pharmacy if dispensed this way). Also, the labeling must have on it the following:
    • animal identification (individual for companion animals, or group or pen if food animal),
    • indication (what condition is the drug being used to treat),
    • number of animals treated (in the case of food animals),
    • dosage, route, and duration of treatment,
    • withdrawal intervals, and,
    • any cautionary statements (for example: not for use in horses intended for food).
  8. AMDUCA does not allow extra-label drug use in animal feeds.
  9. AMDUCA does not permit veterinarians, or pharmacists, to compound unapproved finished new animal drug products from bulk drugs
Conditions for Extra-Label Use in Food Animals
  1. Before prescribing or dispensing an approved new animal or human drug for an extra-label use in food animals, the veterinarian must:
    • make a careful diagnosis and evaluation of the conditions for which the drug is to be used;
    • provide an estimated, scientifically-based, withdrawal interval for the milk, meat, eggs, or other edible products from the treated animal (this information may be obtained by the veterinarian in context of a VCPR from among other sources, scientific literature, academia, or the Food Animal Residue Avoidance Databank (FARAD)2 ;
    • make sure that the identity of the treated animal or animals is maintained;
    • take measures to assure that assigned timeframes for withdrawal are met and no illegal drug residues occur in any food-producing animal subjected to extra-label treatment.
  2. When considering extra-label use of an approved human drug in food animals:
    • the veterinarian must have medical rationale for the use;
    • the veterinarian may not use an approved human drug if an animal drug approved for use in food-producing animals can be used instead for the particular ELU; and
    • if scientific information on the human food safety aspect of the use of the drug in food-producing animals is not available, the veterinarian must take appropriate measures to assure that the animal and its food products will not enter the human food supply.
Compounding Under AMDUCA
FDA defines compounding as the manipulation of drugs to obtain products that differ from the starting materials in an approved dosage form drug. Under AMDUCA, compounding is considered to be extra-label drug use, and must be done from approved finished dosage form human or animal drugs only. Like any extra-label use, compounded drugs should not be used if an approved drug can be used at its approved dose and dosage form. AMDUCA does not permit veterinarians, or pharmacists, to compound unapproved finished new animal drug products from bulk drugs. Unless conditions set forth in 21 CFR 530.13(b) are met, the compounding of a new animal drug from an approved human or animal drug results in an adulterated new animal drug.
Conditions for Compounding
  1. all relevant portions of the regulation have been complied with;
  2. there is no approved new animal or approved new human drug that when used as labeled or in the available dosage form and concentration, will properly treat the condition diagnosed. Compounding from a human drug for use in food-producing animals will not be permitted if an approved animal drug can be used for the compounding;
  3. the compounding is performed by a licensed pharmacist upon the order of a veterinarian or by a veterinarian within the scope of their professional practice;
  4. adequate procedures and processes are followed that ensure the safety and effectiveness of the compounded product;
  5. the scale of the compounding operation is commensurate with the established need for compounded products (e.g., similar to that of comparable practices); and
  6. all relevant State laws relating to the compounding of drugs for use in animals are followed.
Prohibited Drug Uses Under AMDUCA
As described above, AMDUCA allows FDA to place limits on certain extra-label drug uses in animals. These limits include prohibitions of certain extra-label uses. Though The Act provides a stepwise procedure leading to a prohibition, the Agency does not have to take all the steps before prohibiting an extra label use if it finds that the extra-label drug use “presents a risk”.
When assessing the risk from an extra-label drug use, the Agency may inspect a veterinarian’s records. The purpose of the inspection is to document the extent and nature of the extra-label use, not for enforcement reasons. The Agency provides informal public notice when it makes such a finding. If the Agency finds that an extra-label drug use presents a risk, or a required analytical method has not been developed, the Agency may prohibit the use. Any new prohibition ordered by the Agency will be published in the Federal Register, with a ninety-day delayed effective date and a sixty-day comment period. The order will be effective in ninety days, unless it is revoked or modified, or the comment period is extended. When a prohibition or any other important regulatory change is codified, the notice is posted immediately on the CVM web site and disseminated through printed media (FDA Veterinarian, veterinary and trade journals and other sources).
The Current List of Drugs Prohibited From Extra-Label Use (As listed in 21 CFR 530.41)
These drugs (both animal and human), families of drugs, and substances are currently prohibited for extra-label uses in all food-producing animals, (including horses intended for human food):
  • Chloramphenicol
  • Clenbuterol
  • Diethylstilbestrol (DES)
  • Dimetridazole
  • Ipronidazole and other nitroimidazoles
  • Furazolidone, Nitrofurazone, other nitrofurans
  • Sulfonamide drugs in lactating dairy cattle (except approved use of sulfadimethoxine, sulfabromomethazine, and sulfaethoxypyridazine)
  • Fluoroquinolones
  • Glycopeptides
(Editor’s note: This list is complete as of press date, see related article FDA Order Prohibits Extra-Label Use of Phenylbutazone on page 4.)
Conclusion
AMDUCA legalized extra-label use of approved animal and human drugs in animals when that use is under the supervision of a veterinarian and in accordance with FDA regulations. AMDUCA provided veterinarians with privileges comparable to those generally enjoyed by physicians. Veterinarians can protect these privileges by complying with AMDUCA, and understanding the permitted and prohibited extra-label drugs and uses (including compounding).
For more information on AMDUCA, other regulations and policies, and to request hard copies, please visit the CVM Home Page, and look under Quick Index. Notices of proposed rulemaking and final rules, such as additions to prohibited drug list, are announced by Federal Register notices and posted on the CVM Home Page and the FDA Dockets Advanced Publication Display website.
Dr. Comyn is a Consumer Safety Officer in CVM’s Division of Compliance.


Article is found at FDA website located here.

Is Reform of How Animal Drugs are Regulated Needed?

The American Veterinary Medical Association has a question and answer page on its website that can be found  here and below. The questions and answers deal with why a pet owner should not buy over-the-counter (OTC) medications without first discussing it with a veterinarian. The improper use of drugs such as antibiotics can result in drug resistance for certain bacteria.  Why is it that some drugs for animals can be purchased OTC but those same types of drugs cannot be purchased for humans OTC?  Should the FDA treat drugs for animals different than drugs for humans?   Should the FDA take action against businesses that sell these types of drugs such as OTC antibiotics for animals?   Should veterinarians be allowed to compound drugs in their office or should they be required to write a prescription and have a pharmacist fill it? 

Q:
  Why do I need a prescription?

A:

  When you are given a prescription for a medication for your pet, it means that your veterinarian has made a decision that the medication is recommended or necessary to treat your pet's health problem. Many prescription drugs are only effective for specific problems, and may actually be harmful to your pet if used without that critical veterinary examination and diagnosis. Having these drugs available as prescription-only medications ensures that they are used appropriately.

Let's take heartworm preventives as an example. Heartworm preventives are labeled as "prescription-only" because it's critical that your veterinarian makes sure the medication is the right one based on your pet's health status. The preventives target the infective larvae as they are migrating through the tissue prior to reaching the bloodstream and developing to adult heartworms. If your dog (or cat) has heartworms, giving a preventive medication will not effectively treat the disease because the preventives don't readily kill adult heartworms. In some cases, administering preventives to heartworm positive dogs can cause a rapid kill of circulating microfilariae, leading to a life-threatening anaphylactic reaction.

There are drugs, called "over the counter" (OTC) drugs, that don't require prescriptions. Drugs can be bought OTC when the Food and Drug Administration (FDA) determines that the directions for the drug's use aren't overly complicated and are adequate for the public to follow. In some cases, such as the common headache medications for people, the OTC version is just a weaker strength than the prescription form. However, in many cases, a medication is only available with a prescription for the reasons we mention above.




***





Q:
  Why are some spot-on flea and tick preventive medications only available through my veterinarian?


A:
  Some manufacturers have decided to sell their products only through veterinarians so that the veterinarian and pet owner can discuss the situation and work together to determine the best flea and tick treatment for that pet. It's not that the product is "prescription-only" – it's that the manufacturer believes the product should only be sold through veterinarians. In addition, it seems more likely that the product will be used properly (for example, a cat won't be treated with a product labeled only for use in dogs) if the veterinarian is supplying the medication and is counseling the pet owner on the proper use of the medication.

If the spot-on flea and tick product is also labeled for heartworm prevention, it is only available through your veterinarian for the reason we previously described – it is critical that your veterinarian checks for a heartworm infection before your pet is given a heartworm preventive medication.
Q:
  My veterinarian gave me a prescription for a pain reliever for my pet. Why can't I just buy one of the over-the-counter pain relievers at my local drug store?

A:
  Don't do it! Although these products are approved for use in people, many of them are not safe for pets. For example, acetaminophen (Tylenol® is the most common example) can cause severe illness, and even death, in pets. Talk to your veterinarian before you give ANY medication to your pet.
Q:
  Where can I get my pet's prescriptions filled?

A:
  You have several options when your pet needs a prescription medication:
  • You can get it from your veterinarian if they keep it in stock;
  • Your veterinarian can write (or call in) a prescription to a local pharmacy that stocks the medication;
  • Or your veterinarian can provide a prescription so you can get the medication from an online pharmacy.
Q:
  Can I get my pet's prescription medications from Canada?

A:
  No. Drugs from Canada are not approved by the federal government for use in the United States. It is illegal for you to get medications shipped from Canada for yourself or your pet.
Q:
  The pharmacy told me I don't need a prescription for a medication. Is that true? 

A:
  For some OTC medications, it is true. However, if your veterinarian tells you that you need a prescription for the medication but the pharmacy tells you that you don't need it, this might indicate that the pharmacy's staff is either confused or misinformed, or the pharmacy's ethics and standards are questionable. If this happens, talk to your veterinarian, contact the state board of pharmacy, or contact the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA CVM)
Q:
  Why should I consider getting my pet's medications from my veterinarian?

A:
  There are several reasons you should consider getting your pet's medications from your veterinarian:
  • If your veterinarian has the medication in stock, you immediately have it and you don't have to wait to get it from a pharmacy;
  • Your veterinarian or a veterinary technician can answer your questions, provide you with instructions for use, and maybe even demonstrate how to give your pet the medication;
  • If you order from a pharmacy and the medication isn't properly shipped (for example, it is allowed to get too hot or too cold) or isn't properly packaged, it could be ineffective or damaged and unusable; whereas if you get it from your veterinarian, you know it has been properly handled until it reaches you and they can inform you how to make sure you handle the medication properly.
Q:
  If I choose to get my pet's prescriptions filled elsewhere, can my veterinarian refuse to give me a prescription?

A:
  Your veterinarian might strongly recommend that you get the medication directly from them, but some states actually require veterinarians to write prescriptions for clients to have filled elsewhere if requested by the client. Some states do not require this of veterinarians.

There are certainly situations where it is in your pet's best interest to get the medication directly from your veterinarian, and we encourage you to discuss your options with your veterinarian. The AVMA's Principles of Veterinary Medical Ethics recommends that veterinarians comply with their client's wishes and provide written prescriptions if the client prefers having the prescription filled elsewhere.
Q:
  Can my veterinarian charge me a fee for writing a prescription for my pet?

A:
  There is no federal law preventing your veterinarian from charging you a fee for their services and time invested in writing a prescription. Some veterinarians charge a nominal fee for writing prescriptions, but others don't. Individual states might have specific guidance for veterinarians on prescription fees.
Q:
  My veterinarian is telling me that I have to bring my pet in for an examination before they'll write a prescription or authorize a refill. Why?

A:
  According to the AVMA Principles of Veterinary Medical Ethics, it is unethical, and in most states, unlawful, for a veterinarian to write a prescription or dispense a prescription drug outside a Veterinarian-Client-Patient Relationship (VCPR). For more information about the VCPR, including a definition, see Section III of the AVMA's Principles of Veterinary Medical Ethics. For a simpler explanation of the VCPR, read our "Frequently Asked Questions by Pet Owners about the Veterinarian-Client-Patient Relationship."

In order to maintain a VCPR, your veterinarian must see your pet regularly – how regularly they need to see your pet depends on your pet's health. If your pet is on a prescription medicine, your veterinarian may need to reexamine your pet, check blood work, or perform other tests to monitor your pet's response to treatment and determine if the medication needs to be changed. For example, a dog being treated for hypothyroidism needs to be reevaluated regularly to make sure the dosage is having the effect it needs to have.
Q:
  If I choose to get my pet's prescription filled elsewhere, will my veterinarian refuse to see my pet anymore?

A:
  That's not likely. We encourage you to talk to your veterinarian about your concerns and discuss what's best for your pet.
Q:
  Why do some medications cost more from my veterinarian than from an online store? 

A:
  Online pharmacies may buy larger volumes of the medications at a time, so they may get bulk pricing that might be lower (or much lower) than your veterinarian pays - so, even with a markup, some medications from an online source are being sold to you for less than your veterinarian pays to get the medication. Anybody who keeps medications in stock has to mark up the prices above what they paid because of the overhead costs involved in keeping those medications on the shelf and the losses if the medication expires and has to be discarded.
Q:
  What are the risks of ordering from an online pharmacy?

A:
  The amount of risk depends on the quality of the pharmacy. Human error is a risk with any source, but the risk is minimal if the proper procedures are in place.

When you order from an online pharmacy, the product must be shipped to you. If the medication isn't properly shipped (for example, it is allowed to get too hot or too cold) or isn't properly packaged, it could be ineffective or damaged and unusable.

If there is a problem with the medication received from an online pharmacy, there might be a period of time when your pet isn't getting its medication while you wait for the replacement medication to arrive.
Q:
  How do I know the pharmacy is trustworthy?

A:
  Prior experience with a pharmacy is a good indication – ask your veterinarian if there is a pharmacy they recommend. You can also inquire with the state board of pharmacy to determine whether a pharmacy is licensed within the state and the status of the pharmacy's license.

In addition, accreditation by independent bodies can give you more information about an online pharmacy. Two examples of third-party accreditation include the National Association Boards of Pharmacy Vet-VIPPS program and, for compounding pharmacies, the Pharmacy Compounding Accreditation Board. (Your prescription might be called in to a compounding pharmacy if your pet needs a medication tailored just for him or her – an example would be a flavored liquid medication for a cat who otherwise won't take the medication. It is NOT legal, however, to have a compounding pharmacy make a "cheaper" version of an identical product that has been approved by the FDA.)
Q:
  How will I know if there are problems with the medications I get from a pharmacy?

A:
  First of all, talk to your veterinarian about the signs of a problem with the medication. Make sure you know what to look for, and what to do if you see it. Don't hesitate to contact your veterinarian if you are concerned that your pet is having a problem with or a reaction to the medication.

If you receive a shipped medication and the package is damaged or it appears to have been allowed to get too hot or too cold, contact the pharmacy immediately and notify them of the problem. If you are not sure if the medication is safe to use in that condition, contact your veterinarian.

If you have concerns or complaints about a pharmacy's practices or the quality of its products, you can report the pharmacy to your state board of pharmacy.
Q:
  My veterinarian said that my pet needs to get a different dose than what the drug package insert says. Is this legal?

A:
  If your veterinarian thinks the labeled dose isn't right for your pet but a different dose is what your pet needs, this is a federally regulated activity called "extralabel drug use." Basically, if the medication is used in any other way than the label dictates, this is extralabel use, and it is legal as long as your veterinarian follows the regulations. Your veterinarian can also prescribe a human medication for your pet, and this is also considered extralabel use.

Please note that we're only talking about extralabel drug use in pets here. Extralabel use is legal in food-producing animals, but the rules are much more strict.
This FAQ was produced by the AVMA Scientific Activities and Communications Divisions, with assistance from the Council on Biologic and Therapeutic Agents and the Clinical Practitioners Advisory Committee.
Additional resources:
US Food and Drug Administration (FDA)

New Rules in Texas Relating to Veterinary Compounding

The Texas State Board of Veterinary Medical Examiners have adopted rules impacting veterinarian compounding in Texas.  A complete set of all the new rules adopted in Texas can be found here.  The following rule was adopted in the Spring of 2012 and became effective June 14, 2012.  The rules are intended to limit veterinarians from compounding significant quantities of drugs in advance of diagnosis for business profit reason without having established a veterinarian-client relationship  for the patient and diagnosing a condition or disease in that patient.  The adopted rule includes limitations on extralabel drug use in food-producing animals, based on federal regulations and is intended to parallel the requirements for compounded drugs.  The new rule 573.44 provides:

 RULE §573.44 COMPOUNDING DRUGS
(a) A veterinarian may only compound drugs for a specific animal or herd with which the veterinarian has established and maintained a valid veterinarian-client-patient relationship.
(b) A veterinarian may only prescribe compounded drugs to treat a specific occurrence of a disease or condition, which threatens the health of the animal or will cause suffering or death if left untreated, that the veterinarian has observed and diagnosed in the particular patient for whom the compounded drugs are prescribed. The amount of a drug that a veterinarian compounds or orders compounded must not exceed the established need for specific compounded drugs for patients with which the veterinarian has established and maintained a valid veterinarian-client-patient relationship.
(c) Labeling Requirements.
(1) All compounded drugs must bear the labeling information required under §573.40 of this title (relating to Labeling of Medications Dispensed), as well as the following information:
(A) date on which the drug was compounded;
(B) name and strength of medically active ingredients;
(C) identity of treated animals;
(D) withdrawal/withholding times if needed; and
(E) condition or disease to be treated.
(2) In addition to the information listed in paragraph (1) of this subsection, compounded drugs dispensed to the client must also state a date dispensed and an expiration date, which should not exceed the length of the prescribed treatment.
(d) Limitations on Compounded Products.
(1) A veterinarian shall not compound or order a drug compounded if there is a FDA-approved,
commercially available animal or human drug that, when used as labeled or in an extra-label fashion in its available dosage form and concentration, will appropriately treat the patient.
(2) A veterinarian shall only compound or order compounded products with FDA-approved commercially available animal or human drugs as the active ingredients.
(3) A veterinarian shall not promote and/or distribute compounded drugs that are essentially similar to FDAapproved products.
(4) A veterinarian must ensure the safety and efficacy of a compounded drug, including but not limited to avoiding known drug incompatibilities and inappropriate combinations, and must use a pharmacist to perform drug compounding when the complexity of the compounding exceeds the veterinarian's knowledge, skill, facilities, or available equipment.
(e) Compounding for Food Producing Animals.
(1) For animals intended for human consumption, a veterinarian must establish an extended withdrawal interval for the compounded product sufficient to ensure food safety and may not compound from any drugs prohibited for use in food producing animals. The withdrawal period must be supported by scientific information, and the veterinarian shall note the method used to determine the withdrawal interval in the patient records.
(2) A veterinarian shall not compound or order a drug compounded if the compounded drug results in
violative food residue, or any residue that may present a risk to public health.
(3) Compounding from a human drug for use in food-producing animals is not permitted if an approved animal drug can be used for compounding.
(4) Veterinarians shall ensure that procedures are in place to maintain the identity of treated animals, and shall note those procedures in the patient records.
(f) Limitations on Promotion and Sale of Compounded Drugs.
(1) A veterinarian shall not prepare for sale any compounded drugs which employ fanciful names or trade names, colorings or other additives, or that in any way imply that the compounds have some unique effectiveness or composition.
(2) A veterinarian shall not advertise, promote, display, resell, or in any other way market prepared
compounded drugs.
(3) A veterinarian shall not offer compounded drugs to other state licensed veterinarians, pharmacists or other commercial entities for resale.
Source Note: The provisions of this §573.44 adopted to be effective June 14, 2012, 37 TexReg 4229



Here are the boards comments, which can be found here,  on that new rules:

22 TAC §573.44
The Board adopts new §573.44, regarding Compounding Drugs, which sets out the limited circumstances in which a veterinarian can compound a drug.  The adopted new rule parallels current state and federal regulations on the compounding of drugs by veterinarians while emphasizing issues that are of particular significance for veterinarians, such as the importance of the veterinary-client-patient relationship and the limitations on drugs compounded for foodproducing animals. The adopted rule is structured by subject-area, to clarify the limitations that apply to all compounded products, the limitations on compounding for food producing animals, and the limitations on promotion and sale  of compounded drugs. The new adopted rule strengthens the requirement that a veterinarian must establish and maintain a veterinarian-client
-patient relationship with any animal for which the veterinarian compounds drugs. The Board intends the adopted rule to limit drug compounding by veterinarians only  to treat a specific occurrence of a disease or condition that the veterinarian has diagnosed in a specific patient, and to prohibit veterinarians from compounding on any other basis or in quantities greater than those needed for the treatment of the particular disease occurrence in the specific diagnosed patient.   The Board's concern is that some  veterinarians compound significant quantities of drugs in advance of diagnosis for business profit reasons without first diagnosing the condition or disease the compounded drug is designed to treat in a particular patient with whom the veterinarian has established and maintained a  veterinarian-client-patient relationship. Compounding drugs for
office use is allowed under the rule, but only in amounts that do not exceed the established historical need for specific compounded drugs  for patients with which the veterinarian has established and maintained a valid veterinarian-client-patient relationship. The adopted rule includes more detailed provisions requiring that a veterinarian only compound products made with FDA-approved drugs as active ingredients, and not promote or distribute compounds that are essentially the same as other FDA-approved drugs. The subsection of the adopted rule regarding compounding for food-producing animals parallels existing federal and state law on the subject by requiring that the veterinarian set withdrawal times that are based on scientific
information and note the method used to determine the withdrawal period in the patient records, and ensure that procedures are in place to maintain the identity of any food-producing animal that receives a compounded drug. With regard to labeling requirements for compounded drugs, the new adopted rule eliminates redundancies in the labeling information required for all drugs under §573.44, and requires that the label for  compounded drugs include both name and strength of medically active ingredients. 


RULE §573.45 EXTRA-LABEL OR OFF-LABEL USE OF DRUGS provides:
(a) Extra-label or off-label use is the actual or intended use of a drug in an animal that is not in accordance with the approved labeling, and includes, but is not limited to:
(1) compounded drugs;
(2) use in species not listed in the labeling;
(3) use for diseases or other conditions not listed in the labeling;
(4) use at dosage levels, frequencies, or routes of administration other than those stated in the labeling; and
(5) deviation from the labeled withdrawal time based on these different uses.
(b) A veterinarian must use his or her discretion in the off-label use of drugs for animals. In exercising such discretion, a veterinarian shall consider, to the extent possible:
(1) whether the off-label use of a drug meets the community standard of humane care and treatment set out in §573.22 of this title (relating to Professional Standard of Care);
(2) the established safety of the off-label usage;
(3) the inclusion of a drug in a standard veterinary formulary;
(4) analyses of off-label usage in the veterinary medical literature and in articles and commentaries written by the veterinarian's peers in the veterinary medical profession;
(5) information provided by the drug's manufacturer, vendor or the FDA as to whether off-label usage of a drug may present a risk to public health; and
(6) any other sources of pertinent information
(c) If anticipated off-label use of a drug is not commonly accepted or used by average veterinarians in the community in which the veterinarian practices or if the off-label usage does not have an established safety record, the veterinarian shall orally or in writing inform the client that the off-label usage is not commonly accepted or used in the veterinary community and that such usage could pose a risk to the e health of the animal.
Any oral notification shall be recorded in the patient records.

(d) Extra-Label Drug Use in Food Producing Animals.
(1) For animals intended for human consumption, a veterinarian must establish an extended withdrawal interval sufficient to ensure food safety. The withdrawal period must be supported by scientific information, and the veterinarian shall note the method used to determine the withdrawal interval in the patient records.
(2) A veterinarian shall not prescribe an extra-label drug in a manner that will result in violative food residue, or any residue that may present a risk to public health.
(3) Veterinarians shall ensure that procedures are in place to maintain the identity of treated animals, and shall note those procedures in the patient records.
Source Note: The provisions of this §573.45 adopted to be effective June 14, 2012,

The board's comments about rule 573.45 are as follows.
22 TAC §573.45
The Board adopts new §573.45, regarding Extra-Label or Off-Label Use of Drugs, which sets out the conditions under which a veterinarian may prescribe a drug for an off-label use. The adopted new rule includes compounded drugs explicitly among the list of extra-label or offlabel uses for drugs. Although compounding is commonly considered an off-label use, some licensees have expressed confusion over whether the limitations on extra-label use applied to compounded drugs as well as approved drugs. The adopted rule includes limitations on extralabel drug use in food-producing animals, based on federal regulations and is intended to parallel the requirements for compounded drugs set out in adopted new §573.44. 

Saturday, July 7, 2012

The Horse | Equine Drug and Supplement Options Explained

The Horse | Equine Drug and Supplement Options Explained

New Pharmacy Rules in Colorado

In Colorado, the Pharmacy Sunset bill, HB 1311, passed House and Senate and was signed by the Governor. Most law changes went into effect on July 1, 2012.  To review the Pharmacy Sunset Bill, HB 1311, (which is 144 pages) click here.

Virginia Pharmacy Board Statement Regarding Compliance With USP 795 and 797


From Page 4 – July 2012, of The Virginia Board of Pharmacy News found here:

Compliance with USP Standards for
Compounding
Media-fill testing is required when performing low, medium,
and high-risk level compounding of compounded sterile preparations
(CSPs). USP35-NF30 states:
Media-Fill Test Procedure – This test or an equivalent
test is performed at least annually by each person
authorized to compound in a low-risk level environment
under conditions that closely simulate the most
challenging or stressful conditions encountered during
compounding of low-risk level CSPs. Once begun,
this test is completed without interruption. Quality
assurance procedures for medium-risk level CSPs
include all those for low-risk level CSPs, as well as
a more challenging media-fill test passed annually
or more frequently. In addition, a media-fill test that
represents high-risk level compounding is performed
semiannually by each person authorized to compound
high-risk level CSPs.
On June 12, 2012, the Board approved changes to Guidance
Document 110-36. The terms “annually” and “semiannually”
as used in United States Pharmacopeia (USP) Chapters 795 and
797 are defined to mean every 12 months and every six months,
respectively. Records associated with annual and semiannual
requirements shall be maintained for two years from the date
performed. Such records may be maintained in off-site storage
or as an electronic image that provides an exact image of the
document that is clearly legible provided such off-site or electronic
storage is retrievable and made available for inspection or
audit within 48 hours of a request by the Board or an authorized
agent. Board of Pharmacy guidance documents are available at
www.dhp.virginia.gov/Pharmacy/pharmacy_guidelines.htm.

Don't Delay the Response to the issued 483

Don't Delay the Response to the issued 483

Pharmacy compounding or drug manufacturing? FDA's enforcement policy

Pharmacy compounding or drug manufacturing?

On June 15, 2012, the FDA reemphasized its long standing enforcement policies concerning pharmacy compounding in a press release discussing its analysis of compounded hydroxyprogestrerone caproate products. Even though the analysis of limited samples of compounded hydroxyprogestrone caproate did not raise major safety problems, the Agency indicated that compounding of any drug, including hydroxyprogesterone caproate, should not exceed the scope of traditional pharmacy compounding. The FDA generally views the process of reformulating or modifying the drugs already approved by FDA, to fall under traditional pharmacy compounding and within the State’s authority. Such activities are recognized to be analogous to the combining or altering of ingredients by a pharmacist, in response to a licensed practitioner’s prescription, in order to tailor a drug or treatment plan to an individual patient’s special medical needs.
However, should any such activities amount to large-scale compounding production to effectively bypass the New Drug approval provisions of the Federal Food, Drug and Cosmetic Act (“FDCA”), the FDA can exercise its jurisdiction to seek enforcement action against any such practices. The FDA Compliance Policy Guide for Staff and Industry issued in May 2002 provided a list of factors to be considered for a proper determination of whether a pharmacy is engaged in compounding or manufacturing. For example, evidence of receiving and using large quantities of bulk drug substances to prepare large quantities of unapproved drug product in advance of receiving a valid prescription or compounding formulations that are essentially copies of products already approved by the FDA may deem to be a violation of FDCA, and consequently, invite a regulatory action. Historically, the FDA prioritized its enforcement actions related to compounded drugs by assessing the risk-based approach, giving the highest enforcement priority to pharmacies that compound products that are causing harm or that amount to health fraud. To avoid facing an allegation of FDCA violation, early analysis of a given scenario is advisable. The press release is provided in the link below:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm308546.htm

FDA inspectors find serious problems among supplement makers | Business | Dallas Busines...

FDA inspectors find serious problems among supplement makers | Business | Dallas Busines...
CHICAGO — Federal inspections of companies that make dietary supplements — from multivitamins and calcium chews to capsules of echinacea and bodybuilding powders — reveal serious and widespread manufacturing problems in a $28 billion industry that sells products consumed by half of all Americans.
In the last four years, the U.S. Food and Drug Administration has found violations of manufacturing rules in half of the nearly 450 dietary supplement companies it has inspected, according to agency officials.
The inspection reports portray an industry struggling to meet basic manufacturing standards, from verifying the identity of the ingredients that go into its products to inspecting finished batches of supplements.
Some companies don’t even have recipes, known as master manufacturing records, for their products. Others make their supplements in unsanitary factories. New Jersey-based Quality Formulation Laboratories produced protein powder mixes and other supplements in a facility infested with rodents, rodent feces and urine, according to government records. FDA inspectors found a rodent apparently cut in half next to a scoop, according to a 2008 inspection report.
“It’s downright scary,” said Daniel Fabricant, head of the FDA’s Division of Dietary Supplement Programs. “At least half of industry is failing on its face.”
The FDA began conducting inspections in 2008 to assess compliance with new regulations governing the manufacturing, packing and holding of dietary supplements. Since then, 1 in 4 dietary supplement companies inspected by the agency have received a warning letter, considered a significant enforcement action.
So far this year, FDA inspectors have found violations of good manufacturing practices during two-thirds of the 204 inspections they have conducted in nearly 200 supplement facilities, agency officials said. Seventy of these inspections resulted in the agency’s most serious rating.
Cara Welch, vice president of scientific and regulatory affairs for the Natural Products Association, a large dietary supplement trade group based in Washington, D.C., called the inspection numbers “unfortunate” and a significant issue that her organization has been tackling.
“We can’t give up on the industry,” Welch said. “We are going to make it as strong as can be.”
Manufacturers large and small are making significant efforts to implement the regulations, including sections borrowed from the FDA’s drug manufacturing rules, said Michael McGuffin, president of the American Herbal Products Association, a trade association based in Silver Spring, Md.
But it takes time for companies to come into compliance with such a large and complex set of rules and for the FDA to establish how the rules will be enforced, McGuffin said. “Not everybody was in compliance on the day the rule was passed, but that is not uncommon in any rulemaking,” he said.
Fabricant disagreed. The final rule was published in 2007. “You can get a lot done in five years,” he said.
Underscoring the importance of the issue, some customers have suffered serious health problems linked to companies’ poor manufacturing practices.
In 2008, more than 200 people — including a 4-year-old — were poisoned by selenium after taking liquid multivitamin dietary supplements that were sold in health stores and by chiropractors, according to a medical paper published on the mass poisoning. The products, called Total Body Formula and Total Body Mega Formula, contained an average of 40,800 micrograms of selenium per serving instead of 200, according to the paper.
John Adams, of Chipley, Fla., was one of the victims. His silver hair — which had earned him the nickname “Silvertop” at work — began falling out in clumps. His fingernails and toenails became discolored, peeled off, regrew and peeled off again. He had a hard time remembering how to do his job as a telephone repairman. He became so weak that it was hard to get in and out of his work truck, and eventually he was forced to retire.
Adams and his wife, who also experienced problems, sued along with dozens of others. This year, the couple received a settlement. Adams, now 65, said he is still weak on his left side, has ruined fingernails and toenails that do not grow and struggles with memory problems.
“What is a person in America to do to be healthy?” Adams wrote in an e-mail. “Who can you trust? Not the supplement industry because it does not take long for a tainted product to make you very sick.”
Rod Cate, attorney for Total Body Essential Nutrition, the distributor of the products, wrote in an e-mail that his client had been in business for more than 10 years with no problems and with satisfied customers before the companies that manufactured Total Body Formula produced the tainted bottles. Cate wrote that the problem was caused by contractors incorrectly interpreting the formula, incorrectly formulating it, or both. The company is in the midst of settling lawsuits, he wrote.
“Not sure if FDA inspections of manufacturing facilities would have made any difference as this was a problem with formulation and not a problem with the manufacturing facilities themselves,” Cate wrote. Fabricant called the Total Body Formula incidents “a classic case” of not adhering to good manufacturing practices. “This is why these things are important,” he said.

Read more here: http://www.star-telegram.com/2012/07/06/4083566/fda-inspectors-find-serious-problems.html#storylink=cpy